Bank of Montreal’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$93.1K Hold
13,668
– – ﹤0.01% 3255
2026
Q1
$61.1K Sell
13,668
-40
-0.3% -$186 ﹤0.01% 3245
2025
Q4
$75.4K Buy
13,708
+40
+0.3% +$194 ﹤0.01% 3111
2025
Q3
$44.7K Buy
+13,668
New +$38.7K ﹤0.01% 3147
2023
Q2
– Sell
-49,084
Closed -$40.2K – 4293
2023
Q1
$40.2K Sell
49,084
-153,115
-76% -$198K ﹤0.01% 3410
2022
Q4
$459K Buy
+202,199
New +$409K ﹤0.01% 2660
2021
Q2
– Sell
-268
Closed -$5K – 4872
2021
Q1
$5K Sell
268
-1,096
-80% -$29.7K ﹤0.01% 4669
2020
Q4
$38K Buy
+1,364
New +$29.4K ﹤0.01% 4090

Other funds holding TSHA

Bank of Montreal's TSHA Position: Q2 2026 in Review

Bank of Montreal held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 13,668 shares worth $93.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3255.

Bank of Montreal first reported a position in TSHA in Q4 2020 and has held it in 8 quarters since. The position peaked at $459K in Q4 2022. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Bank of Montreal held 13,668 shares of Taysha Gene Therapies worth $93.1K as of Q2 2026.
  • Bank of Montreal left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #3255 holding.
  • Bank of Montreal first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 8 quarters since.
  • Bank of Montreal's Taysha Gene Therapies position peaked at $459K in Q4 2022.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.